Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial

Journal of Medical Economics

Volumn 13, Issue 3, 2010, Pages 428-437

  Ohsfeldt, Robert L ^a   Gandhi, Sanjay K ^b   Smolen, Lee J ^c   Jensen, Marie M ^d   Fox, Kathleen M ^e   Gold, Alex ^b   Hsia, Judith ^b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b ASTRAZENECA   (United Kingdom)

^c Medical Decision Modeling Inc   (United States)

^d ASTRAZENECA R AND D   (Sweden)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Cost benefit analysis; Rosuvastatin

Indexed keywords

PLACEBO; ROSUVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; LONG TERM CARE; MORBIDITY; MORTALITY; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION;

AGED; CARDIOVASCULAR DISEASES; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MONTE CARLO METHOD; PYRIMIDINES; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SULFONAMIDES; SURVIVAL ANALYSIS; UNITED STATES;

EID: 77956670562     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.499758     Document Type: Article

References (34)

1. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239
2. DeBacker G, Ambosioni E, Borch-Johnson K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-1610
3. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565
4. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207
5. Gold MR, Siegel JE, Russell LB, et al., eds. Cost-effectiveness in Health and Medicine. Oxford: Oxford University Press, 2006
6. Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477-1486
7. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11:1-160, iii-iv
8. Glynn RJ, Danielson E, Fonseca FAH, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009;360:1-11
9. Aries E. United States life tables, 2004. Natl Vital Stat Rep 2007;56(9)9:1-39. (http://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56-09.pdf, accessed 12/12/2008)
10. Heron M. Deaths: leading causes for 2004. Natl Vital Stat Rep 2007;56(5)9:1-95. (http://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56-05. pdf, accessed 12/12/2008)
11. Framingham Heart Study 2008. Coronary Heart Disease (10-year risk). (http://www.framinghamheartstudy.org/risk/coronary.html, accessed 4/23/09)
12. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279:1458-1462
13. Food and Drug Administration, Center for Drug Evaluation and Research. Generic Competition and Drug Prices http://www.fda.gov/CDER/ogd/generic- competition.htm, accessed 5/3/2007
14. U.S. Department of Labor, Bureau of Labor Statistics 2009. Consumer Price Index Databases -Urban Consumers (All Items) (http://www.bls.gov/cpi/data.htm, accessed 4/1/09)
15. Sullivan P, Arant T, Ellis S, et al. The cost-effectiveness analysis of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics 2006;10:1021-1033
16. ShihYT, HanS, Cantor SB. Impact of generic drug entry on cost-effectiveness analysis. Med Decis Making 2005;25:71-80
17. Hoyle M. Future drug prices and cost-effectiveness analyses. Pharmacoeconomics 2008;26:589-602
18. Pharmaceutical Management Agency. Prescription for pharmacoeconomic analysis. Methods for cost-utility analysis. (http://www.pharmac.govt.nz/ schedule.asp. accessed 12/4/2009)
19. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003;163:1637-1641
20. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000;20:332-342
21. Cutler DM, Rosen AB, Vijan S. The value of medical spending in the United States, 1960-2000. N Engl J Med 2006;355:920-927
22. Heart Protection Study Collaborative Group. Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes 2009;2:65-72
23. Pignone M, Earnshaw S, Tice J, et al. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006;144:326-336
24. US National Hospital Discharge Survey. 2006. Available at http://www.cdc.gov/nchs/about/major/hdasd/nhds.htm
25. Society of Cardiothoracic Surgeons of Great Britain and Ireland. UK Cardiac Surgical register. 2006. Available at http://www.scts.org
26. British Cardiovascular Intervention Society. PCI Database. 2005. Available at http://www.bcis.org.uk
27. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med 2005;142: 251-259
28. Beinart SC, Kolm P, Veledar E, et al. Long-term cost-effectiveness analysis of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention. J Am Coll Cardiol 2005;46:761-769
29. Chan PS, Nallamothu BK, Gurm HS, et al. Incremental benefit and cost-effectiveness of high dose statin therapy in high risk patients with coronary heart disease. Circulation 2007;115:2398-2409
30. Kauf TL, Velazquez EJ, Crosslin DR, et al. The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. Am Heart J 2006;151:206-212
31. Puskas JD, Williams WH, Mahoney EM, et al. Off-pump vs. conventional coronary artery bypass grafting: early and 1-year graft patency, cost, and quality-of-life outcomes. JAMA 2004;291:1841-1849
32. O'Brien C, Gage B. Cost and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005;293:699-706
33. Lee WC, Christensen MC, Josh, AV, et al. Long-term cost of stroke subtypes among Medicare beneficiaries. Cerebrovasc Dis 2007;23: 57-65
34. Scuffham PA, Kosa J. The cost-effectiveness of fluvastatin in Hungary following successful percutaneous coronary intervention. Cardiovasc Drugs Ther 2006;20:309-317